A body mass index of 30 or higher, or a BMI of 27 paired with a documented weight-related condition such as hypertension or type 2 diabetes, is typically what insurers require before they will pay for medications like Wegovy or Zepbound. FDA labeling sets the medical floor, while each insurer writes its own administrative rules on top, so the same patient can be approved under one formulary and denied under another.
Your height, weight, comorbidity list, and prior weight-loss attempts all feed the reviewer’s decision.
This roadmap walks you through the BMI thresholds insurers follow, the FDA pathways that determine which GLP-1 even qualifies, the comorbidities that strengthen an approval, and the documentation that turns a denial into a yes.
Why BMI Is the Gateway to GLP-1 Coverage
Body mass index, calculated by dividing weight in kilograms by height in meters squared, is the blunt instrument most insurers use to decide whether obesity treatment qualifies for coverage. Under standard CDC thresholds, a BMI of 25 to 29.9 falls in the overweight range, while 30 and above crosses into obesity. That single number tends to drive more approvals and denials than any other clinical detail, and your recorded height and weight directly shape it.
Medical vs. Insurance Thresholds
FDA labeling for chronic weight management typically calls for a BMI of 30 or higher, or 27 with at least one weight-related comorbidity. Insurers mirror that language in their policies, but they often add their own wrinkles: a required three-to-six month record of supervised diet and exercise, a specific ICD-10 diagnosis code on the claim, or proof that cheaper medications were tried first.
The result is two parallel hurdles, one clinical and one administrative, and your chart has to clear both.
Why an Accurate Baseline Matters
BMI depends entirely on the height and weight recorded at the visit, so small errors propagate. A patient measured at 5 feet 4 inches and 174 pounds lands at 29.9, technically overweight and outside the policy. The same patient at 175 pounds reaches 30.0, inside it. Bring dated weight logs, recent clinic notes, and any home scale records to your first appointment, because reviewers want to see the trend, not a single snapshot.
That documentation pressure exists because approval flows through one of two FDA routes, each with its own clinical evidence bar.
| Your BMI Range | CDC Classification | Typical Insurance Stance |
|---|---|---|
| 18.5 to 24.9 | Normal weight | No coverage for weight-loss GLP-1 |
| 25.0 to 29.9 | Overweight | Possible coverage only with a documented comorbidity |
| 30.0 to 34.9 | Obesity, class I | Coverage typically available |
| 35.0 to 39.9 | Obesity, class II | Coverage commonly available |
| 40.0 and above | Obesity, class III | Coverage usually available |
The Two FDA Pathways for GLP-1 Approval
Wegovy, which contains semaglutide, and Zepbound, which contains tirzepatide, are the only two GLP-1 receptor agonists the FDA has approved specifically for chronic weight management in adults without diabetes. The rest of the class, including Ozempic and Mounjaro, carries diabetes-only labeling, and that labeling difference is what trips up most claims. Your prescription choice has to match the indication on the label, or the reviewer will reject it.
Weight-Management Approvals
The FDA greenlit Wegovy in 2021 for chronic weight management in adults carrying a BMI of 30 or higher, or 27 alongside at least one weight-related condition. Zepbound followed in 2023, with a similar threshold. Both belong to a class originally developed for type 2 diabetes, but their weight-loss trials involved non-diabetic adults, which is why insurers treat them as the standard-bearers for obesity treatment.
Choosing one of these two keeps your prior authorization aligned with the FDA-approved indication.
Diabetes-Only Approvals
Ozempic and Mounjaro remain FDA-approved for type 2 diabetes alone, which means insurers reject weight-loss claims almost reflexively. A prescription written “for weight loss” using Ozempic triggers an automatic denial on most formularies. Prescribers can legally write the medication off-label, but reimbursement follows the label, not the prescription pad, so your out-of-pocket cost jumps to full list price.
Pathway choice alone rarely carries a case, though, since comorbidities documented alongside it often tip the decision.
| Medication | FDA Approval | Insurance Stance for Weight Loss |
|---|---|---|
| Wegovy (semaglutide) | Chronic weight management | Routinely covered when criteria are met |
| Zepbound (tirzepatide) | Chronic weight management | Routinely covered when criteria are met |
| Ozempic (semaglutide) | Type 2 diabetes | Weight-loss claims routinely denied |
| Mounjaro (tirzepatide) | Type 2 diabetes | Weight-loss claims routinely denied |
If your prior authorization gets bounced, the most common reason is that the wrong GLP-1 was selected for the indication on the claim.
Comorbidities That Strengthen an Approval
A comorbidity is a second health condition that exists alongside obesity, and insurers lean heavily on these to decide whether a BMI of 27 crosses into payable territory. A patient at 29.9 without any documented comorbidity often gets denied, while the same patient with a sleep apnea diagnosis gets approved. Your comorbidity list, properly coded and dated, can be the deciding factor between approval and a denial letter.
The Five Most Recognized Conditions
Type 2 diabetes tops the list because it has the longest history of GLP-1 use and the most clinical guidelines behind it. Hypertension, dyslipidemia (abnormal cholesterol levels), and obstructive sleep apnea round out the cardiovascular-metabolic cluster that most reviewers scan for.
Atherosclerotic cardiovascular disease and a history of stroke or heart attack fall into the same bucket, especially since the FDA expanded Wegovy’s label in 2024 to include cardiovascular risk reduction in adults with obesity and established heart disease.
How Documentation Makes the Difference
A diagnosis written only in a progress note rarely carries weight at a utilization review. Chart notes with a date, an ICD-10 code (E66 for obesity itself), and supporting data, like an A1C result for diabetes or a polysomnography report for sleep apnea, give the reviewer something concrete to check off. Bring prior lab work, blood pressure logs, or sleep study summaries to your appointment so the prescriber can attach them to the prior authorization request.
Those records only matter once they’re assembled into a packet the insurer cannot easily reject.
Building a Prior Authorization Package That Gets Approved
A prior authorization is the insurer’s gatekeeping form, a request the prescriber submits to justify coverage before the pharmacy fills the script. The package usually includes the diagnosis, the BMI calculation, a letter of medical necessity, and proof that you met the plan’s step therapy rules. Missing paperwork is the single biggest reason for denials, more than BMI itself, so your goal is to leave no box unchecked.
Required Components
The prescribing physician must submit a prior authorization form that lists your BMI, the ICD-10 code E66, and a clear statement of medical necessity. Most carriers also want proof of three to six consecutive months of structured diet and exercise, often documented through a weight management program, a registered dietitian’s notes, or a fitness app export. Your letter of medical necessity, recent labs, and a dated weight-tracking log shorten the review cycle and reduce follow-up requests.
Common Pitfalls
Filling out the wrong formulary form for the wrong GLP-1 derails the request before it reaches a reviewer. Forgetting the comorbidity letter, or attaching notes that don’t mention the second diagnosis, also stalls approvals. Submit the package through the plan’s portal whenever possible, because faxed forms tend to get lost in the queue and a missing page resets the clock on your appeal timeline.
Call the plan’s prior authorization department and ask which two or three GLP-1 medications sit on the preferred tier. Matching your request to a covered drug doubles the odds of approval.
Plan-by-Plan Differences in GLP-1 Coverage
Coverage rules vary sharply across Medicare, Medicaid, ACA marketplace plans, and employer-sponsored insurance, so the same patient with the same BMI can face four different answers. Knowing which plan pays for which drug saves you weeks of appeals, and the formulary PDF is your single best source of truth.
Employer and Marketplace Plans
Rising costs have pushed many employer-sponsored plans to exclude weight-loss GLP-1s, though others still list Wegovy or Zepbound on formulary tier 2 or 3 with prior authorization. The formulary PDF, usually posted on the insurer’s website, spells out which medications are covered and what step therapy applies. Pull that document before scheduling your appointment so the prescriber matches the request to a covered drug on the first try.
Medicare and Medicaid
Medicare Part D does not cover medications prescribed solely for weight loss, including Wegovy and Zepbound, creating a coverage gap for older adults with obesity. The 2024 expansion of Wegovy for cardiovascular risk reduction opens a narrow door: patients with established heart disease plus obesity may qualify for Part D coverage of Wegovy under the cardiovascular indication. State Medicaid programs and ACA marketplace plans vary widely, so checking your specific formulary PDF is essential before scheduling an appointment.
| Plan Type | Typical Coverage | Key Caveat |
|---|---|---|
| Employer-sponsored (large group) | Often covered with prior authorization | Increasing exclusions in 2024 to control cost |
| ACA marketplace | Varies by state and carrier | Check the specific plan’s formulary PDF |
| Medicare Part D | Limited coverage for cardiovascular indication | Weight-loss-only use excluded |
| State Medicaid | Varies significantly by state | Some states exclude weight-loss GLP-1 entirely |
When Coverage Is Denied and How to Reverse It
A denial letter looks final, but most denials reverse on appeal, especially when the original packet lacked comorbidity evidence or used the wrong diagnosis code. The appeals process is bureaucratic, but the success rate is meaningful, and your willingness to push through one or two rounds usually determines the outcome.
Internal Appeals and Peer-to-Peer Reviews
An internal appeal asks the plan to re-review the same prior authorization with new clinical documentation attached. A peer-to-peer review goes further: the prescribing physician calls the plan’s medical director and argues the case in real time. Both approaches overturn a meaningful share of denials, particularly when the original packet omitted a comorbidity letter or a structured weight-loss attempt log.
External and Backup Routes
When internal channels stall, a complaint filed with the state insurance commissioner can force a plan to revisit the case. Manufacturer savings programs, including the savings cards offered by Novo Nordisk and Eli Lilly, reduce the cash price for eligible patients. Self-pay for these medications typically runs $900 to $1,400 per month without insurance, so a savings card or compounded alternative is often the difference between staying on therapy and stopping.
Persistent denials usually signal a missing diagnosis code or an unmatched formulary drug. Fix the paperwork before filing a third appeal, or the same reviewer will reject the same packet again.
The Bottom Line
BMI sets the floor, FDA labeling sets the ceiling, and your plan’s formulary decides the final verdict. A clean prior authorization package, paired with documented comorbidities and the right GLP-1 for the indication, gets most patients across the line on the first or second try. Treat every denial as a paperwork problem first and a policy problem second, because the data usually fixes itself when the right documents reach the reviewer.
FAQ
What BMI do you need to qualify for GLP-1 medications?
Insurers typically require a BMI of 30 or higher, or a BMI of 27 with a documented weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnea. BMI thresholds for medical eligibility and insurance coverage tend to mirror each other, and your recorded measurements drive both numbers.
Will insurance pay for Wegovy if you don’t have diabetes?
Yes, when the plan covers chronic weight management and you meet the BMI threshold. Wegovy carries FDA approval for weight loss independent of diabetes status, which is what most reviewers look for on the prior authorization form.
How do you get a prior authorization for semaglutide?
Your prescribing physician submits a prior authorization form through the plan’s portal, including your BMI, the ICD-10 code E66, a letter of medical necessity, and proof of structured diet and exercise attempts over three to six months. Supporting labs and a comorbidity letter shorten the review cycle.
Can you get a GLP-1 with a BMI of 27?
Coverage at a BMI of 27 is possible but requires at least one documented weight-related comorbidity and prior attempts at lifestyle modification. Plans often treat a BMI of 27 as the boundary case that needs the strongest paperwork, so your packet should include every supporting record you can gather.
What comorbidities help insurance approve weight loss drugs?
Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and established cardiovascular disease are the most widely accepted weight-related conditions. Each one should be documented in your medical record with chart notes, lab results, or imaging reports before the prior authorization goes in.
Why was my GLP-1 prior authorization denied?
The most common reasons include a BMI below the plan’s threshold, a missing comorbidity letter, an unmatched diagnosis code, or selection of a GLP-1 whose FDA labeling does not cover the requested indication. Reviewing the denial letter’s specific cited reason and resubmitting with the missing documentation usually reverses the decision on appeal.
